Share on LinkedInShare on LinkedIn

ARTICLE · 17 AUGUST 2020

When Half A Glass Is An Empty Glass

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Holding: In IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., --F.3d__ (Fed. Cir. July 31, 2020), the U.S. Court of Appeals for the Federal Circuit

United StatesIntellectual Property

Holding: In IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., --F.3d__ (Fed. Cir. July 31, 2020), the U.S. Court of Appeals for the Federal Circuit (Judges PROST, Reyna, and Hughes) affirmed the district court's decision that certain IBSA's claims were invalid as indefinite.

Background: IBSA's U.S. Pat. 7,723,390, claim 1, reads: A pharmaceutical composition comprising thyroid hormones or their sodium salts in the form of either:

  1. a) a soft elastic capsule consisting of a shell of gelatin material containing a liquid or half-liquid inner phase ..., said liquid or half-liquid inner phase being in direct contact with said shell without any interposed layers, or
  2. b) a swallowable uniform soft-gel matrix .... (emphasis added.)

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from